What is it about?
Glutathione (GSH)/Glutathione S-transferases (GST) is increased in various types of human cancer diseases, such as lung, breast, colon, kidney, ovary, esophagus, and stomach. A newly synthesized set of benzimidazole derivatives inhibited glutathione–S-transferase (GST) and in vitro attenuated the growth of some cancer cell lines such as human breast and colon cancer cell lines (MCF7 and HCT, respectively).
Featured Image
Why is it important?
Developing of new GSTs inhibitors constitutes a promising approach in anticancer chemotherapy to overcome the problem of multi-drug resistance.
Perspectives
Synthesis of new compounds that specifically inhibit the various classes of GST will continue to be one of the most important and worthwhile rationale to gain novel agents that could be utilized as adjuvants or chemotherapeutics of different cancer diseases or ameliorate the problem of the anticancer drug resistance.
manal anwar
National Research Centre/Cairo/ Egypt
Read the Original
This page is a summary of: Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents, Future Medicinal Chemistry, December 2017, Future Science,
DOI: 10.4155/fmc-2017-0137.
You can read the full text:
Contributors
The following have contributed to this page
